SEATTLE, Aug. 10, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial results for the second quarter ended June 30, 2017 and provided an update on its corporate activities.
“PhaseRx continued to make solid progress in the second quarter of 2017 with the receipt of orphan drug designation for PRX-OTC from the European Medicines Agency,” said Robert W. Overell, Ph.D., president and chief executive officer of PhaseRx.
